SCHEMBL485683

SCHEMBL485683

NCc1cccc(CC(N)C(=O)O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 9/20 0.67
PTGS1 P23219 2/20 0.67
ALPI P09923 1/20 0.67
PKM P14618 1/20 0.67
XIAP P98170 1/20 0.67
GRIA2 P42262 1/20 0.62
NOS3 P29474 3/20 0.60
NOS1 P29475 3/20 0.60
NOS2 P35228 3/20 0.60
KDM4E B2RXH2 1/20 0.57
USP2 O75604 1/20 0.57
EGFR P00533 1/20 0.57
LCK P06239 1/20 0.57
FYN P06241 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
ALOX15 P16050 1/20 0.57
HTR2A P28223 1/20 0.57
PTGS2 P35354 1/20 0.57
RECQL P46063 1/20 0.57
HIF1A Q16665 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL485684 1.00 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL29351918 1.00 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL6371428 1.00 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL15656470 0.95 SLC7A5 (0.76) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2314258 0.93 SLC7A5 (0.77) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL366883 0.89 SLC7A5 (0.85) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL14945063 0.86 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31688862 0.86 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL25451922 0.86 NOS1 (0.49) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31369893 0.86 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024030977-A2 NOVEL MELANOCORTIN ANALOGS SIGHTSTREAM BIOTHERAPEUTICS, INC. (US) 2024-02-08 WO claimed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 US claimed
US-9101662-B2 Compositions with modulating agents FOAMIX PHARMACEUTICALS LTD. (IL) 2015-08-11 US claimed
US-20150166606-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS RA PHARMACEUTICALS, INC. 2015-06-18 US claimed
US-8795693-B2 Compositions with modulating agents FOAMIX LTD. (IL) 2014-08-05 US claimed
EP-2097065-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS Foamix Ltd. (IL) 2009-09-09 EP claimed
WO-2008152444-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS FOAMIX LTD. (US) 2008-12-18 WO claimed
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions FOAMIX LTD. (IL) 2008-08-28 US claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US claimed
EP-4747882-A1 DATA STORAGE USING PROTEINS The Hong Kong Polytechnic University (CN) 2026-05-27 EP disclosed
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS MERCK SHARP & DOHME LLC (US) 2026-04-30 US disclosed
EP-4729094-A2 Modulators of complement activity UCB Holdings, Inc. (US) 2026-04-22 EP disclosed
EP-4727655-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP disclosed
EP-4727653-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP disclosed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US disclosed
EP-0787010-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-06 EP disclosed
US-5518735-A ANTICOAGULANTS ADMINISTERED BY MOUTH PENTAPHARM AG (CH) 1996-05-21 US disclosed
WO-1996012499-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-02 WO disclosed
EP-0511347-A1 META-SUBSTITUTED PHENYL ALANINE DERIVATIVES Pentapharm A.G. (CH) 1992-11-04 EP disclosed
WO-1992008709-A1 META-SUBSTITUTED PHENYL ALANINE DERIVATIVES PENTAPHARM AG (CH) 1992-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions CUTA, SLTM, SMO SLC7A5 4410/4885PTGS1 84/4885ALPI 1437/4885
US-20150166606-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS KLKB1, KLK1, KLK5 SLC7A5 2730/4885PTGS1 1388/4885ALPI 3771/4885
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS IL1A, IL1B, IL1RN SLC7A5 3532/4885PTGS1 217/4885ALPI 2772/4885
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP SLC7A5 21/4885PTGS1 3737/4885ALPI 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.